Medical news today: Monday, November 9, 2026
FDA investigates malignancy reports after Zolgensma; MHRA issues interim monitoring advice for givinostat; regulators update cell and gene therapy guidance
Get tomorrow's issue in your inbox.
- 01
FDA finalises potency-assurance guidance for cell and gene therapies
Source: US FDA
A November 6 regulatory roundup reports the FDA issued final guidance describing a science- and risk-based approach to potency assurance across the lifecycle of cellular and gene therapy products. The recommendations cover development, manufacturing controls, analytical methods and post-approval monitoring, with attention to product-specific variability and evidence that each batch has the intended biological activity.
Why it mattersPotency is central to demonstrating that complex biologic and gene-therapy products consistently deliver their intended effect. The guidance is relevant to CMC strategy, assay qualification, batch release and lifecycle control planning. More on Approvals & regulatory →
- 02
FDA grants accelerated approval to Rybrevant Faspro for recurrent or metastatic head and neck cancer
Source: US FDA
A November 6 regulatory roundup reports the FDA granted accelerated approval to amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for adults with recurrent or metastatic head and neck squamous cell carcinoma after progression on platinum-based chemotherapy and immunotherapy. The reported supporting evidence included an objective response rate of 42% in 102 patients; confirmatory studies are required to verify clinical benefit.
Why it mattersThe approval is a regulatory milestone for a population with limited options after prior treatment. Because it is accelerated approval, follow-up evidence and confirmatory trial outcomes remain important to the benefit-risk assessment. More on Approvals & regulatory →
- 03
FDA investigates malignancy reports linked to Zolgensma gene therapy
Source: US FDA
The FDA said it is investigating postmarketing reports of malignancies in patients treated with onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy. The agency described reports involving several tumour sites and confirmed cases of vector DNA integration involving the GLI1 oncogene. The FDA is evaluating the evidence; this is an investigation, not a new conclusion that every reported tumour was caused by treatment.
Why it mattersThis is an important postmarketing safety topic for gene-therapy pharmacovigilance. Case assessment should distinguish spontaneous reports, molecular evidence and confirmed causal attribution, while clinicians and families should follow current product information and regulator communications. More on Approvals & regulatory →
- 04
MHRA issues interim risk-mitigation advice for givinostat after reports of deaths
Source: MHRA / GOV.UK
The MHRA reported several international deaths in patients with Duchenne muscular dystrophy receiving givinostat and issued interim risk-mitigation advice pending further review. The advice includes enhanced ECG and electrolyte monitoring at specified points. The agency stated that no UK deaths had been reported in the notice and advised patients not to stop prescribed treatment without speaking to their specialist.
Why it mattersThe update illustrates how emerging postmarketing safety information can lead to targeted monitoring while a regulator reviews the evidence. Pharmacovigilance teams should track the source notice, product information changes and any subsequent regulatory communication. More on Approvals & regulatory →
More recent digests
- Wednesday, November 18, 2026White House pulls its FDA nominee, the US loses measles elimination status, and FDA offers to share its approval reviews with other regulators
- Tuesday, November 17, 2026US flu deaths in children rise, a Cochrane review backs daily iron for anaemia, and the FDA approves giredestrant for selected breast cancers
- Monday, November 16, 2026Teen tirzepatide trial cuts BMI, US flu season starts early, and the FDA rejects Summit's lung cancer drug
- Sunday, November 15, 2026WHO issues first type 1 diabetes guidance for adults and children; JAMA reports a possible CTE blood biomarker; MP flags mercury creams
- Saturday, November 14, 2026FDA approves a weekly self-injected myasthenia gravis drug; US measles deaths rise; India enforces lower cancer-drug prices
- Friday, November 13, 2026WHO reports persistent TB burden; JAMA publishes new oncology and neonatal sepsis trials; MHRA flags a packaging defect
- Thursday, November 12, 2026WHO reports continuing Ebola emergency and African regulatory advances; FDA approves first FXIa inhibitor for secondary stroke prevention
Free daily email
The day's approvals, safety signals and trials, in five minutes.
Join the list with just your email. You can also follow the RSS feed.
